Voyager Therapeutics, Inc. (VYGR) Financials
VYGR Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 294.7 million | 118.4 million |
2023-06-30 | 315.5 million | 116.5 million |
2023-03-31 | 336.3 million | 119.3 million |
2022-12-31 | 159.4 million | 100.3 million |
VYGR Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -21.8 million | 2.9 million |
2023-06-30 | -2.0 million | 2.7 million |
2023-03-31 | 123.1 million | 2.6 million |
2022-12-31 | -13.2 million | 2.3 million |
VYGR Net Income
No data available :(
VYGR Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 252.9 million | - | 21.0 million |
2023-06-30 | 272.7 million | - | 21.7 million |
2023-03-31 | 273.3 million | - | 22.4 million |
2022-12-31 | 118.8 million | - | 23.1 million |
VYGR Shares Outstanding
VYGR Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 782000 | 25.9 million | 8.3 million | - |
2023-06-30 | 1.2 million | 22.0 million | 8.3 million | - |
2023-03-31 | 509000 | 18.6 million | 9.0 million | - |
2022-12-31 | 933000 | 14.6 million | 8.5 million | - |
VYGR Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 4.6 million | 945000 |
2023-06-30 | 4.9 million | 1.1 million |
2023-03-31 | 150.5 million | 1.1 million |
2022-12-31 | -41.1 million | 834000 |
VYGR
Price: $8.81
52 week price:
Earnings Per Share: 2.97 USD
P/E Ratio: 6.42
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 275000
Ebitda: -22.9 millionMarket Capitalization: 479.5 million